Purchase this article with an account.
Vittorio Capuano, OUBRAHAM-MEBROUKINE Hassiba, Benjamin Wolff, Salomon Y Cohen, Catherine P Garcher, Jean-Francois Korobelnik, Ramin Tadayoni, Christian Delhay, Audrey Derveloy, Eric H Souied; Ranibizumab in patients with neovascular age-related macular degeneration in real-world clinical settings in France: 1-year data from the LUMINOUS™ study. Invest. Ophthalmol. Vis. Sci. 2016;57(12):534. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
LUMINOUS™ (NCT01318941; initiated March 2011) is the largest, prospective, observational, global study in the field of medical retina. LUMINOUS™ is an ongoing 5-year study that is designed to evaluate the long-term safety, effectiveness, treatment patterns, and health-related quality of life associated with ranibizumab (RBZ) 0.5 mg treatment across all approved indications in 30,000 patients from routine clinical practice. We present the 1-year data from the French patients included in LUMINOUS™.
Overall, 17, 545 adult patients with neovascular age-related macular degeneration (nAMD) were enrolled before March 2014; of these 9125 adult nAMD patients with a potential for 1-year follow-up were enrolled before March 2013. We analyzed the baseline characteristics of nAMD patients that were enrolled in France before March 2014 and the 1-year data from the French cohort.
Baseline characteristics of the French and the global nAMD cohorts are shown in Table 1. Both the French and the global cohorts had similar mean baseline visual acuity (VA; Early Treatment Diabetic Retinopathy Study [ETDRS] letter score; French/global nAMD cohorts: VA, 58.6/54.3). A higher proportion of patients in the French cohort had pigment epithelium detachment (PED) than those in the global cohort (68.0% versus 42.4%). In the global cohort, the 1-year data showed that on average treatment-naïve patients gained VA from baseline whilst those previously treated with RBZ either gained or maintained VA, with a relatively low number of injections and visits (Table 2). The 1-year data for the French cohort are expected in February 2016.
The French nAMD patients enrolled in the LUMINOUS™ study were slightly older and had similar baseline VA, a higher proportion had PED, and a similar proportion had non-ocular comorbidities at baseline compared with the global nAMD cohort. The 1-year follow-up data from the French cohort will provide an invaluable source of information from a diverse group of patients currently underrepresented in randomized clinical trials.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
Table 1. Baseline characteristics of the French and the global nAMD patients enrolled before March 2014
Table 2. Outcomes at Year 1 of the global nAMD patients enrolled before March 2013
This PDF is available to Subscribers Only